Literature DB >> 27255819

Braak stage and trajectory of cognitive decline in noncognitively impaired elders.

Elliott J Mufson1, Michael Malek-Ahmadi2, Noelle Snyder2, Jake Ausdemore2, Kewei Chen2, Sylvia E Perez3.   

Abstract

In a previous cross-sectional study, we found that nondemented elderly participants from the Rush Religious Orders Study (RROS) displayed a wide range of Braak neurofibrillary tangle and amyloid plaque pathology similar to that seen in prodromal and frank Alzheimer's disease. Here, we examined longitudinal changes in cognitive domains in subjects from this cohort grouped by Braak stage using linear mixed effects models. We found that the trajectory of episodic memory composite (EMC), executive function composite (EFC), and global cognitive composite scores (GCS: average of EMC and EFC scores) was significantly associated with age at visit over time, but not with Braak stage, apolipoprotein E (APOE) ε4 status or plaque pathology alone. By contrast, the combined effects of Braak stage, APOE status, and age at visit were strongly correlated with the trajectory of EMC, EFC and GCS performance over time. These data suggest that age and APOE ε4 status, rather than Alzheimer's disease-related pathology, play a more prominent role in the trajectory of cognitive decline over time in this elderly nondemented population. However, the findings reported require confirmation in a larger cohort of cases.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Alzheimer's; Cognition; Dementia; Longitudinal; Neurofibrillary tangles

Mesh:

Substances:

Year:  2016        PMID: 27255819      PMCID: PMC4894536          DOI: 10.1016/j.neurobiolaging.2016.03.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  51 in total

1.  Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition.

Authors:  Kathryn P Riley; Gregory A Jicha; Daron Davis; Erin L Abner; Gregory E Cooper; Nancy Stiles; Charles D Smith; Richard J Kryscio; Peter T Nelson; Linda J Van Eldik; Frederick A Schmitt
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 2.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

3.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

Review 4.  Hippocampal plasticity during the progression of Alzheimer's disease.

Authors:  E J Mufson; L Mahady; D Waters; S E Counts; S E Perez; S T DeKosky; S D Ginsberg; M D Ikonomovic; S W Scheff; L I Binder
Journal:  Neuroscience       Date:  2015-03-12       Impact factor: 3.590

5.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

6.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.

Authors:  Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

Review 7.  Apolipoprotein E and Alzheimer disease.

Authors:  W J Strittmatter; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

8.  Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.

Authors:  R Katzman; R Terry; R DeTeresa; T Brown; P Davies; P Fuld; X Renbing; A Peck
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

9.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  12 in total

1.  Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.

Authors:  Chelsea T Tiernan; Stephen D Ginsberg; Bin He; Sarah M Ward; Angela L Guillozet-Bongaarts; Nicholas M Kanaan; Elliott J Mufson; Scott E Counts
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

2.  Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease.

Authors:  Sylvia E Perez; Muhammad Nadeem; Michael H Malek-Ahmadi; Bin He; Elliott J Mufson
Journal:  Neurodegener Dis       Date:  2017-07-26       Impact factor: 2.977

3.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

4.  HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.

Authors:  L Mahady; M Nadeem; M Malek-Ahmadi; K Chen; S E Perez; E J Mufson
Journal:  Neuropathol Appl Neurobiol       Date:  2018-10-28       Impact factor: 8.090

5.  Early Alzheimer-type lesions in cognitively normal subjects.

Authors:  Stergios Tsartsalis; Aikaterini Xekardaki; Patrick R Hof; Enikö Kövari; Constantin Bouras
Journal:  Neurobiol Aging       Date:  2017-10-13       Impact factor: 4.673

6.  Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison.

Authors:  Daniele Altomare; Camilla Caprioglio; Frédéric Assal; Gilles Allali; Aline Mendes; Federica Ribaldi; Kelly Ceyzeriat; Marta Martins; Szymon Tomczyk; Sara Stampacchia; Alessandra Dodich; Marina Boccardi; Christian Chicherio; Giovanni B Frisoni; Valentina Garibotto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-27       Impact factor: 9.236

7.  Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.

Authors:  Nicolai Franzmeier; Emrah Düzel; Frank Jessen; Katharina Buerger; Johannes Levin; Marco Duering; Martin Dichgans; Christian Haass; Marc Suárez-Calvet; Anne M Fagan; Katrina Paumier; Tammie Benzinger; Colin L Masters; John C Morris; Robert Perneczky; Daniel Janowitz; Cihan Catak; Steffen Wolfsgruber; Michael Wagner; Stefan Teipel; Ingo Kilimann; Alfredo Ramirez; Martin Rossor; Mathias Jucker; Jasmeer Chhatwal; Annika Spottke; Henning Boecker; Frederic Brosseron; Peter Falkai; Klaus Fliessbach; Michael T Heneka; Christoph Laske; Peter Nestor; Oliver Peters; Manuel Fuentes; Felix Menne; Josef Priller; Eike J Spruth; Christiana Franke; Anja Schneider; Barbara Kofler; Christine Westerteicher; Oliver Speck; Jens Wiltfang; Claudia Bartels; Miguel Ángel Araque Caballero; Coraline Metzger; Daniel Bittner; Michael Weiner; Jae-Hong Lee; Stephen Salloway; Adrian Danek; Alison Goate; Peter R Schofield; Randall J Bateman; Michael Ewers
Journal:  Brain       Date:  2018-04-01       Impact factor: 13.501

8.  Static and Dynamic Cognitive Reserve Proxy Measures: Interactions with Alzheimer's Disease Neuropathology and Cognition.

Authors:  Michael Malek-Ahmadi; Sophie Lu; YanYan Chan; Sylvia E Perez; Kewei Chen; Elliott J Mufson
Journal:  J Alzheimers Dis Parkinsonism       Date:  2017-10-25

9.  Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.

Authors:  Shaomin Li; Ming Jin; Lei Liu; Yifan Dang; Beth L Ostaszewski; Dennis J Selkoe
Journal:  Acta Neuropathol Commun       Date:  2018-11-08       Impact factor: 7.801

10.  Cognitive composite score association with Alzheimer's disease plaque and tangle pathology.

Authors:  Michael Malek-Ahmadi; Kewei Chen; Sylvia E Perez; Anna He; Elliott J Mufson
Journal:  Alzheimers Res Ther       Date:  2018-09-11       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.